Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. (Q43031095)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Maria Teresa Torres-Salido

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Josefina Cortés-Hernández

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alfonso Segarra Medrano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Miquel Vilardell Tarrés

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Josep Ordi-Ros

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

10 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

Nephrology Dialysis Transplantation

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

3939-3948

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20538787%20AND%20SRC:MED&resulttype=core&format=json

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Therapeutic options for resistant lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Long-term treatment of lupus nephritis with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Prognostic factors in lupus nephritis. Contribution of renal histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

European consensus statement on the terminology used in the management of lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Update on the management of lupus nephritis: let the treatment fit the patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ322